Richard Armer, chief scientific officer of Redx Pharma Plc (LON:REDX), believes the company’s new ROCK2 inhibitor drug has the potential to be a “best-in-class agent” for the treatment of fibrotic diseases of the kidney and liver.
His comments came at the conclusion of the American Society of Nephrology’s Kidney Week, in San Diego, California, at which Redx made a poster presentation hailing the potential of using the therapy to tackle chronic kidney disease.
Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells.
In an animal model of acute kidney injury, the Redx selective ROCK2 compound reduced damage and the expression of inflammatory and profibrotic genes in the kidney.
In addition, a rat study indicated that the Redx inhibitor avoided cardiovascular side-effects.
"We are pleased that our poster was presented at the high profile American Society of Nephrology Kidney Week,” said Armer.
“We believe our highly selective ROCK2 inhibitors have the potential to be best-in-class agents for the treatment of fibrotic diseases of the kidney such as diabetic nephropathy and of the liver such as non-alcoholic steatohepatitis.
“This is the first publication of our ROCK2 project data and we are delighted that the high quality of our research has been recognised by the ASN."